Shire Test Prep

Additional Recommendations


At the follow-up, the patient reported no problem with the use of LACRISERT® (hydroxypropyl cellulose ophthalmic insert). I instructed her to continue with the therapy, along with the other aspects of her regimen. Additionally, I introduced and discussed advanced dry eye treatments with the patient, telling her that we were holding them in reserve for use should her condition warrant. These include autologous serum drops and amniotic membrane placement.

Many patients with Sjögren’s syndrome will have to consider such advanced therapies as their ocular condition progresses. Because initiating these types of treatments can be a particular challenge in this patient population, I find it extremely helpful to introduce potential follow-on therapies at an early point. Regardless of efficacy, each of these therapies has its own challenges. An amniotic membrane placement will blur vision for a while; autologous serum will require the patient to be vigilant about its storage. Having an early discussion makes patients aware of their options and prepares them to incorporate such treatments if and when the time comes.

Douglas K. Devries, OD
Douglas K. Devries, OD, is a co-founder and managing partner of Eye Care Associates of Nevada and serves as both clinical director and optometric residency program director for the state-wide practice. He is an adjunct clinical professor of optometry at Pacific University and serves on the advisory board or speakers' bureau of Abbott Medical Optics, Alcon, Allergan, Akorn, Bio Tissue, BVI Medical, Bausch + Lomb, TearLab, NiCox, OcuSoft, and Ophthalmic Resources.

Indications and Usage

LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.

Important Safety Information

  • LACRISERT® (hydroxypropyl cellulose ophthalmic insert) is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose.
  • Instructions for inserting and removing LACRISERT should be carefully followed.
  • If improperly placed, LACRISERT may result in corneal abrasion. Because LACRISERT may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery.
  • The following adverse reactions have been reported, but were in most instances mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.

Please see full Prescribing Information for LACRISERT® (hydroxypropyl cellulose ophthalmic insert).



Eye Care Professionals Only

The information included on this website is intended for US healthcare professionals. By agreeing, you acknowledge that you are a licensed US healthcare professional.